SCD DRC A Phase 3 Randomized, Double-Masked, Parallel Group, Multicenter Study to Compare the Efficacy, Safety, Tolerability, Pharmacokinetics and Immunogenicity between SCD411 and Eylea® in Subjects with Neovascular Age-related Macular Degeneration
Research Grant
Administered By
Ophthalmology
Awarded By
Sam Chun Dang Pharm. Co., Ltd
Start Date
September 1, 2019
End Date
December 31, 2022
Administered By
Ophthalmology
Awarded By
Sam Chun Dang Pharm. Co., Ltd
Start Date
September 1, 2019
End Date
December 31, 2022